Korean scientists discover a groundbreaking method to transform ordinary fibroblasts into mature cardiomyocytes Researchers at Korea University have achie...
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Fa...
Shuttle Pharmaceuticals Holdings, Inc. a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson&rs...
Viatris Inc. (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of ceneri...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they ...
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...
Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...
Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...
© 2025 Biopharma Boardroom. All Rights Reserved.
